Gosset Ownership
Private
Employees
~50
Therapeutic Areas
Stage
Preclinical
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Avammune Therapeutics General Information
Avammune has identified a first-in-class small molecule inhibitor of ADAR1 (AVA-ADR-001) which has demonstrated significant IFN response in vitro. The company is preparing for IND enabling studies and safety studies for their immuno-oncology assets.
Contact Information
Website
Primary Industry
Biotech
Corporate Office
Philadelphia, Pennsylvania
United States
United States
Drug Pipeline
Pre-clinical
Key Partnerships
In discussions with major pharma and biotech companies for clinical translation
Avammune Therapeutics Funding
No funding data available
To view Avammune Therapeutics's complete valuation and funding history, request access »